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he 
 

 
-catenin signaling pathway is deregulated in
nearly all colon cancers. Nonhypercalcemic vitamin
 
D3 (1
 

 
,25-dehydroxyvitamin D
 
3
 
) analogues are can-
didate drugs to treat this neoplasia. We show that these
compounds promote the differentiation of human colon
carcinoma SW480 cells expressing vitamin D receptors
(VDRs) (SW480-ADH) but not that of a malignant subline
(SW480-R) or metastasic derivative (SW620) cells lacking
VDR. 1
 

 
,25(OH)
 
2
 
D
 
3
 
 induced the expression of E-cadherin
 
and other adhesion proteins (occludin, 
 
Zonula occludens
 
[ZO]-1, ZO-2, vinculin) and promoted the translocation of
 

 
-catenin, plakoglobin, and ZO-1 from the nucleus to the
T
 
plasma membrane. Ligand-activated VDR competed with T
 
cell transcription factor (TCF)-4 for 
 

 
-catenin binding.
Accordingly, 1
 

 
,25(OH)
 
2
 
D
 
3
 
 repressed 
 

 
-catenin–TCF-4
transcriptional activity. Moreover, VDR activity was en-
hanced by ectopic 
 

 
-catenin and reduced by TCF-4. Also,
 
1
 

 
,25(OH)
 
2
 
D
 
3
 
 inhibited expression of 
 

 
-catenin–TCF-
4-responsive genes, c-
 
myc
 
, peroxisome proliferator-acti-
vated receptor 
 

 
, 
 
Tcf-1
 
,
 
 
 
and CD44, whereas it induced ex-
pression of ZO-1. Our results show that 1
 

 
,25(OH)
 
2
 
D
 
3
 
 in-
duces E-cadherin and modulates 
 

 
-catenin–TCF-4 target
genes in a manner opposite to that of 
 

 
-catenin, promoting
the differentiation of colon carcinoma cells.
 
Introduction
 
Colon cancer is the third cause of cancer death in Western
countries and a major health problem worldwide (Parker et
al., 1997). Colon carcinogenesis is the result of the progres-
sive transformation of colonic epithelial cells, which accu-
mulate mutations that increase their proliferation and alter
their phenotype.
E-cadherin is a transmembrane linker protein of the inter-
cellular adheren junctions that play a key role in the mainte-
nance of the adhesive and polarized phenotype of epithelial
cells (Takeichi, 1995; Gumbiner, 1996). Loss of E-cadherin
expression is a common event during the transition from ad-
enoma to carcinoma, which involves the alteration of the
normal epithelial phenotype and the acquisition of invasive
capacity (Birchmeier and Behrens, 1994; Perl et al., 1998;
Christofori and Semb, 1999). E-cadherin is regarded as a tu-
mor suppressor gene and its loss as a predictor of poor prog-
nosis (Vleminckx, et al., 1991; Takeichi, 1993; Mareel et al.,
1994; Guilford et al., 1998). 
 

 
-Catenin is a protooncogene
encoding a cytoskeleton-associated protein, which in normal
epithelial cells is bound mostly to the cytoplasmic tail of
E-cadherin at the adherens junctions (for review see Morin,
1999). Free cytosolic 
 

 
-catenin levels are strictly controlled
by phosphorylation of the NH
 
2
 
-terminal region of the pro-
tein by glycogen synthase kinase (GSK)* 3
 

 
. This reaction
requires association with axin/conductin and the product of
the adenomatous polyposis coli (APC) tumor suppressor
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
 
,25(OH
 
2
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3
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
 
,25-dihydroxyvi-
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3
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Zonula occludens
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gene, and targets 
 

 
-catenin for ubiquitin-mediated degrada-
tion by the proteasome (Rubinfeld et al., 1996; Behrens et
al., 1998; Kishida et al., 1998). Interaction of Wnt ligands
with their membrane receptors blocks GSK-3
 

 
, leading to
the accumulation of free 
 

 
-catenin (for reviews see Eastman
and Grosschedl, 1999; Peifer and Polakis, 2000). In the cell
nucleus, 
 

 
-catenin binds members of the T cell transcription
factor (TCF)/lymphoid enhancer-binding factor (LEF)-1
family and thus regulates gene expression (Behrens et al.,
1996; Huber et al., 1996; Billin et al., 2000). Nearly all colon
tumors present a deregulated 
 

 
-catenin signaling pathway by
mutation of either APC or 
 

 
-catenin, which leads to the
blockade of phosphorylation by GSK-3
 

 
, resulting in 
 

 
-cate-
nin stabilization (Inomata et al., 1996; Korinek et al., 1997;
Morin et al., 1997), reduced APC-regulated nuclear export
(Henderson, 2000; Rosin-Arbesfeld et al., 2000), and per-
haps higher specific activity (Guger and Gumbiner, 2000).
As a result, 
 

 
-catenin accumulates in the nucleus, leading to
both the activation of genes involved in the control of cell
proliferation and invasiveness such as c-
 
myc
 
, cyclin D1, per-
oxisome proliferator-activated receptor (PPAR) 
 

 
, matrilysin,
c-
 
jun
 
, 
 
fra
 
1, uPA receptor, fibronectin, CD44, 
 
Tcf
 
-1, Cdx-1
and gastrin, and the loss of expression of DRCTNNB1A and
differentiated epithelial markers such as 
 
Zonula occludens
 
(ZO)-1 (He et al., 1998, 1999; Crawford et al., 1999; Gradl
et al., 1999; Mann et al., 1999; Tetsu and McCormick,
1999; Roose et al., 1999; Vera et al., 1999; Kawasoe et al.,
2000; Koh et al., 2000; Lickert et al., 2000). Mutations in
the TCF-4 gene may also contribute to this process (Duval et
al., 2000). In addition, APC mutations may also be responsi-
ble at least in part for chromosomal instability in colon can-
cer cells (Fodde et al., 2001; Kaplan et al., 2001).
Epidemiological data suggest an inverse correlation be-
tween vitamin D dietary intake or sunlight exposure and hu-
man colorectal cancer (Garland et al., 1989; Newmark and
Lipkin, 1992). Vitamin D, especially its most active metabo-
 
lite 1
 

 
,25-dihydroxyvitamin D
 
3
 
 (1
 

 
,25[OH]
 
2
 
D
 
3
 
), not only
contributes to calcium homeostasis but also regulates cell
proliferation and differentiation (Saez et al., 1993; Xi and
Feldman, 1993; Buras et al., 1994; Kane et al., 1996).
1
 

 
,25(OH)
 
2
 
D
 
3
 
 and several synthetic vitamin D derivatives
(deltanoids), which show reduced calcemic activity such as
EB1089, MC903, and KH1060, inhibit the growth of epi-
thelial, melanoma, soft tissue sarcoma, and leukemic cells by
inducing cell cycle arrest or apoptosis (Diaz et al., 2000; Park
et al., 2000). Furthermore, they inhibit the invasive capacity
in vitro, the synthesis of several invasion-associated proteins
(Hansen et al., 1994; González-Sancho et al., 1998; Koli and
Keski-Oja, 2000), and the tumor-induced angiogenesis (Ma-
jewski et al., 1993) of breast cancer cells, and they show a
chemopreventive activity in animal models of colorectal and
breast cancer (Akhter et al., 1997; van Weelden et al., 1998).
Vitamin D and its analogues regulate gene expression by
binding to specific vitamin D receptors (VDRs) of the nu-
clear receptor superfamily, which are ligand-modulated tran-
scription factors (for review see McDonald et al., 2001).
Upon ligand activation, VDR binds specific nucleotide se-
quences (vitamin D response elements, VDREs) in target
genes to activate or repress their expression through multiple
but ill-defined interactions with coactivator complexes and
components of the basal transcription machinery (for review
see McDonald et al., 2001). Several vitamin D target genes
 
have been characterized in several tumor cell types such as
c-
 
myc
 
, p21
 
Waf
 
, p27
 
Kip1
 
, tenascin-C, fibronectin, laminin and
its receptor, apolipoprotein D, insulin-like growth factor
binding protein 3, cyclin C, and several members of the
transforming growth factor family and their receptors (Freed-
man, 1999). Two studies have reported the regulation of
epidermal growth factor receptor expression (Tong et al.,
1998) or the cross-talk between vitamin D and tumor
growth factor 
 

 
 signaling pathways (Yanagisawa et al.,
1999), although the physiological relevance of these mecha-
nisms remains unclear.
VDR is expressed in the normal colonic mucosa, slightly
increases in the hyperplasic condition, and is clearly lower in
late stages of carcinogenesis (Vandewalle et al., 1994). Ac-
cordingly, high VDR expression is associated with favorable
prognosis in colorectal cancer patients, suggesting that these
receptors are involved in this pathogenesis and their poten-
tial role as a predictive marker (Shabahang et al., 1993;
Evans et al., 1998). Several clinical trials are underway to as-
sess the activity of several vitamin D derivatives in patients
with colorectal carcinoma and other neoplasias (Gross et al.,
1998; Gulliford et al., 1998; Smith et al., 1999). However,
their molecular and cellular mechanisms of action in colon
carcinoma cells remain mostly unknown.
The SW480 cell line is one of the best characterized hu-
man colorectal cancer lines, and it has been widely used as a
model system for the study of this neoplasia. It was estab-
lished in 1976 from a primary human Duke’s B colon ade-
nocarcinoma of a 50-yr-old patient (Leibovitz et al., 1976).
SW480 cells harbor most of the genetic abnormalities that
 
characterize advanced colon cancers such as activation of K-
 
ras
 
oncogene, c-
 
myc
 
 amplification, deletion of chromosome 18,
and mutation of APC and p53 tumor suppressor genes (To-
mita et al., 1992; Schwarte-Waldhoff et al., 1999). In addi-
tion, these cells are defective for E-cadherin and express high
levels of nuclear 
 

 
-catenin, transforming growth factor 
 

 
,
and epidermal growth factor receptors (Tomita et al., 1992).
We used the SW480 cell line to examine the mechanism of
action of 1
 

 
,25(OH)
 
2
 
D
 
3
 
 and several nonhypercalcemic ana-
logues in colon cancer cells. Our results show that these
compounds have a prodifferentiation phenotypic effect on
 
VDR-positive SW480 cells parallel to the induction of
 
E-cadherin, induce 
 

 
-catenin nuclear export, and inhibit
 

 
-catenin gene regulatory activity. Moreover, 1
 

 
,25(OH)
 
2
 
D
 
3
 
promotes a direct VDR–
 

 
-catenin interaction, which may
decrease TCF-4–
 

 
-catenin complexes and may thus consti-
tute another mechanism of inhibition of 
 

 
-catenin signaling.
 
Results
 
1
 

 
,25(OH)
 
2
 
D
 
3 
 
induces the differentiation 
of a VDR-positive subpopulation of SW480 
cells to an epithelial-like phenotype
 
To investigate its mechanism of action in human colon can-
cer cells, two cell lines from the same patient, SW480 cells es-
tablished from a primary adenocarcinoma and SW620 from
a lymph node metastasis, were treated with 1
 

 
,25(OH)
 
2
 
D
 
3
 
.
Upon 1
 
,25(OH)2D3 addition, a proportion of SW480 cells
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changed in shape and properties to a more adhesive epithelial
phenotype (Fig. 1 A, a and b), whereas the rest of the SW480
population and SW620 cells were unaffected (Fig. 1 A, a,
b, g, and h). These two distinct responses in SW480 cul-
tures correlated with two cell morphologies: flat, polygonal,
and adherent to plastic dishes, which corresponded to
1,25(OH)2D3-responsive cells, and rounded, refractile, and
less adherent, which corresponded to nonresponsive cells
(Fig. 1 A, a and b, arrows). This is consistent with previous
reports of the existence of two populations in SW480 cell
cultures (Tomita et al., 1992; Baulida et al., 1999) and led us
to obtain clonal sublines of each cell type: SW480-ADH (ad-
herent) and SW480-R (rounded). In agreement with the pre-
vious finding, the two established sublines retained their dis-
tinct morphology and hormonal response for 2 yr: upon
addition of 1,25(OH)2D3, the bulk of SW480-ADH cells
acquired an epithelial-like phenotype, forming compact is-
lands (Fig. 1 A, c and d), whereas SW480-R cells were unaf-
fected (Fig. 1 A, e and f). Moreover, SW480-R cells were
highly tumorigenic in athymic mice (eight of eight tumors
were generated 9 wk after the subcutaneous injection of 106
cells), whereas in contrast SW480-ADH cells were weakly tu-
morigenic (3 of 24). The distinct behavior of these cell types
was attributable to differences in the expression of VDR,
which was checked in Northern blot assays (Fig. 1 B). VDR
mRNA levels were high in the SW480-ADH subline
and three times lower in parental SW480 cells. In con-
trast, SW620 cells expressed a very low level of VDR
mRNA, which was undetectable in SW480-R cells. Further,
1,25(OH)2D3 increased the expression of a transfected lu-
ciferase reporter gene cloned under the control of four copies
of a direct repeat (DR) VDRE (4  VDRE) in SW480-
ADH and to a lesser extent in parental SW480 cells but had
no effect in SW480-R or SW620 cells (Fig. 1 C). In addi-
tion, cotransfection of an exogenous VDR clearly induced
the luciferase gene in all cell types (Fig. 1 C). Thus, the VDR
expressed by SW480 and SW480-ADH cells was an active
mediator of the gene regulatory activity of 1,25(OH)2D3,
whereas SW480-R and SW620 cells did not respond to this
agent, owing to the lack of endogenous VDR expression. In
agreement with these results and its effect in other cell types
(Buras et al., 1994; Kane et al., 1996), 1,25(OH)2D3 inhib-
ited the proliferation of SW480-ADH cells and to a lesser ex-
tent that of SW480 cells, whereas SW480-R and SW620
cells were totally unresponsive (Fig. 1 D). We tested whether
the reexpression of VDR reverted the malignant phenotype
of SW480-R cells. However, no clones of SW480-R cells sta-
bly expressing VDR were obtained in any of three experi-
ments carried out using various vectors that were functional
in other cell systems, suggesting that VDR, perhaps by inhib-
iting cell growth, counterselects these cells and thus hampers
clonal expansion.
1,25(OH)2D3 induces E-cadherin transcription 
and regulates the expression and localization 
of other adhesion proteins
To examine the effect of 1,25(OH)2D3 on the phenotype
of SW480-ADH cells, we performed immunofluorescence
and confocal laser microscopy analyses of several epithelial
markers. Although SW480 cells have been described as
E-cadherin–defective (Sadot et al., 1998; Baulida et al.,
1999; Orsulic et al., 1999), SW480-ADH cells exhibited low
but detectable membrane-bound expression of this intercellu-
lar adhesion protein that was drastically increased upon treat-
ment with 1,25(OH)2D3 (Fig. 2 A, a–c). The induction of
E-cadherin expression correlated with the phenotypic change:
it was observed as soon as 16 h after treatment, was especially
high at 48 h, and lasted 7 d (Fig. 2 A, a–c). Like parental
SW480 and other colon cancer lines defective for APC and
E-cadherin, SW480-ADH cells showed high -catenin levels
in the nucleus and cytoplasm (Fig. 2 A, d). Remarkably,
1,25(OH)2D3 severely altered the subcellular location of
-catenin, from predominantly nuclear to a nearly exclusive
plasma membrane distribution (Fig. 2 A, d–f). This paralleled
the induction of E-cadherin, which was maximal 48 h after
1,25(OH)2D3 addition and agreed with the reported seques-
tration of -catenin at the plasma membrane compartment
after transient transfection of SW480 cells with E-cadherin
(Sadot et al., 1998; Orsulic et al., 1999).
1,25(OH)2D3 also progressively increased the amount of
occludin and ZO-2, two components of the tight junctions
that are located predominantly at the plasma membrane
(Fig. 2 B, a–c and d–f, respectively). ZO-1, another compo-
nent of these structures, was also enhanced (see Fig. 6). We
also studied the effects of 1,25(OH)2D3 on the expression
of vinculin, a protein located in tight junctions, adherens
junctions, and focal adhesion plaques (Watabe-Uchida et al.,
1998). Untreated SW480-ADH cells showed a punctate
staining of vinculin at the cell periphery, which probably
corresponded to focal adhesion plaques (Fig. 2 B, g). 2 d af-
ter 1,25(OH)2D3 addition, an increased dotted basal, but
not apical, vinculin staining was observed (Fig. 2 B, h–i),
whereas at 7 d after treatment both basal and apical surfaces
were strongly stained, revealing the relocalization of vinculin
in intercellular junctional structures (Fig. 2 B, j–k). Alto-
gether, these data indicated that 1,25(OH)2D3 induces the
expression of intercellular adhesion proteins in SW480-
ADH cultures. The acquisition of the adhesive phenotype
and the formation of compact islands increased with the du-
ration of 1,25(OH)2D3 treatment and depended on the
presence of this agent in the medium, since its removal led to
progressive cell disaggregation. Finally, 1,25(OH)2D3 also
relocated -catenin/plakoglobin from the nucleus and cyto-
plasm to the plasma membrane (unpublished data).
To determine whether the induction of occludin, ZO-1,
and ZO-2 led to the formation of functional tight junctions,
we measured the transepithelial electrical resistance (TER)
of SW480-ADH cell monolayers grown on porous filters. As
expected from their tumoral origin and spindle shape, un-
treated SW480-ADH cells showed no significant TER. In
contrast, cells treated for 4 wk with 1,25(OH)2D3 dis-
played low but detectable TER when seeded on filters (day
0), which progressively increased (fourfold) on the following
days, revealing the formation of functional tight junctions
(Table I). The requirement for long 1,25(OH)2D3 treat-
ments to induce TER (1–2 wk were insufficient) suggests
that additional unknown proteins must be induced with
slow kinetics and/or that the establishment of adequate mo-
lecular interactions is a slow process.
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Figure 1. Effect of 1,25(OH)2D3 on human colon carci-
noma cells expressing variable levels of VDR. (A) Phase–
contrast micrographs of various cell lines upon 48-h treat-
ment with 1,25(OH)2D3 (107 M) or vehicle (control): 
SW480 (a and b); SW480-ADH (c and d); SW480-R (e and f); 
SW620 (g and h). The two distinct cell types found in SW480 
cultures are indicated in a and b: flat, polygonal, and 
1,25(OH)2D3-sensitive (white arrows), and 1,25(OH)2D3-
rounded 1,25(OH)2D3-unresponsive (black arrows). (B) Northern blot analysis of VDR and RXR expression in SW480, SW480-ADH, 
SW480-R, and SW620 cells untreated or treated with 107 M 1,25(OH)2D3 for 48 h. 10 	g of poly(A)
 RNA was loaded per lane. GAPDH 
was used as internal control. (C) 1,25(OH)2D3 transcriptional responsiveness of each cell line. Cells were transfected with the 4  VDRE–
DR3-tk-luc construct and a human VDR expression vector as indicated. After 48-h incubation in the presence or absence of 1,25(OH)2D3 
(107 M), luciferase activity in total cell extracts was measured as described in Materials and methods. A -galactosidase expression vector 
was also transfected as internal control. Mean values and standard deviations of the mean obtained in three experiments using triplicates are 
shown. (D) Effect of 1,25(OH)2D3 on DNA synthesis. Cells were untreated or treated with the indicated 1,25(OH)2D3 concentrations for
48 h, and the level of DNA synthesis was measured by estimating the incorporation of labeled thymidine in TCA-precipitable material as de-
scribed in Materials and methods. Mean values and standard deviations of the mean obtained in three experiments using duplicates are 
shown. , SW480 cells; , SW480-R cells; , SW480-ADH cells; , SW620 cells.
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Figure 2. Induction of epithelial markers by 1,25(OH)2D3 in SW480-ADH cells. (A) Analysis by immunofluorescence and confocal laser 
scanning microscopy of the expression of various adhesion proteins in cells treated with 107 M 1,25(OH)2D3 for the indicated times or left 
untreated (control): E-cadherin (a–c); -catenin (d–f). (B) Same as in A with longer treatments: a–c, occludin; d–f, ZO-2; g–k, vinculin. Vincu-
lin expression was analyzed at two sections: basal (g, i, and k) and apical (h and j). Bars, 10 	m.
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Given that adherens junctions are essential to intercellular
adhesion and epithelial polarity and that E-cadherin plays a
role in these structures, we explored the mechanism by
which 1,25(OH)2D3 induces this protein. Northern blot-
ting revealed that a 48-h treatment with 1,25(OH)2D3
substantially increased (five- to sixfold) the level of E-cad-
herin 4.6 kb mRNA in SW480-ADH cells but not in cells
lacking VDR (SW480-R and SW620) (Fig. 3 A). In con-
trast, the amount of -catenin 3.4 kb mRNA was unaf-
fected, and comparable levels, slightly lower in SW480-R,
were detected in the three cell lines. In agreement with these
results, a strong increase in the level of E-cadherin protein
but no change in that of -catenin were found upon
1,25(OH)2D3 treatment (Fig. 3 B). Other hormones act-
ing through members of the nuclear receptor superfamily
such as dexamethasone, thyroid hormone, and all-trans reti-
noic acid failed to induce E-cadherin expression, showing
the specificity of 1,25(OH)2D3 (Fig. 3 C; unpublished
data). Likewise, 9-cis retinoic acid, whose retinoid X recep-
tor (RXR) is the common partner of VDR, was ineffective
by itself, and it did not alter the induction of E-cadherin by
1,25(OH)2D3 (Fig. 3 C; unpublished data). This strongly
suggests that ligand activation of VDR is sufficient for
E-cadherin induction by RXR-VDR heterodimers. We then
studied the kinetics of the induction of E-cadherin mRNA
in SW480-ADH cells by 1,25(OH)2D3. The induction
was abrupt with a rapid increase (10-fold) 4 h after addition
and a peak at 8 h (12.5-fold) followed by a slow decay
(Fig. 3, D and F). Accordingly, the cellular content of
E-cadherin protein increased by 7-fold at 16 h and by 13-
fold at 48 h after treatment (Fig. 3, E and F).
Transcription and translation inhibitors (actinomycin
D and cycloheximide, respectively) were used to under-
stand the E-cadherin induction. Actinomycin D completely
blocked the effect of 1,25(OH)2D3, whereas cyclohexi-
mide strongly inhibited it (Fig. 4 A). This indicates that
1,25(OH)2D3 induces E-cadherin expression by a tran-
scriptional mechanism that requires protein synthesis de
novo. Since 1,25(OH)2D3 interacts with the phosphoino-
sitol 3-kinase and protein kinase C–signaling pathways in
various cell types (Gniadecki et al., 1997; Hmama et al.,
1999), we aimed to elucidate whether this also occurs in
SW480-ADH cells. However, the induction of E-cadherin
was unaffected by inhibitors of phosphoinositol 3-kinase
(wortmannin, Ly294002), and it was only partially affected
(30% reduction in RNA increase at 4 h) by a protein kinase
C antagonist (bisindolylmaleimide), suggesting that these
two signaling pathways are not relevant to the activity of
1,25(OH)2D3 (unpublished data). The induction of E-cad-
herin transcription by 1,25(OH)2D3 was tested in transient
transfection experiments using two distinct constructs: ei-
ther a short 270-bp (178 to 
92) or a long 1,072-bp
(987 to 
92) fragment of the human gene promoter
controlling the expression of the luciferase reporter gene.
Consistently, a 1.8-fold induction of the large promoter
construct but not of the small one was observed (Fig.
4 B). Further supporting the transcriptional effect of
1,25(OH)2D3, no induction was detected when mutant
forms of VDR (AF2), lacking the COOH-terminal AF-2
domain responsible for transcriptional activation or harbor-
ing inactivating point mutations in this region (L417S and
E420Q), were transfected (unpublished data). The discrep-
ancy between the level of induction of the promoter con-
struct used and the higher increase in E-cadherin mRNA
content induced by 1,25(OH)2D3 in SW480-ADH cells
may be due to the lack of additional regulatory sequences in
the available promoter region studied and/or effects on RNA
stability. We ruled out the second hypothesis by analyzing
whether 1,25(OH)2D3 modulated the half-life of E-cad-
herin mRNA in SW480-ADH cells: the decay in E-cad-
herin mRNA content was the same in untreated and in
1,25(OH)2D3-treated cells (Fig. 4 C).
1,25(OH)2D3 causes -catenin to translocate from 
the nucleus to E-cadherin complexes at the plasma 
membrane and inhibits its gene regulatory activity
Exogenous E-cadherin induces -catenin relocation by nu-
clear export and the formation of E-cadherin–-catenin
complexes at the plasma membrane in SW480 and other cell
lines lacking endogenous E-cadherin (Sadot et al., 1998; Or-
sulic et al., 1999). Since 1,25(OH)2D3 induced E-cadherin
expression in SW480-ADH cells, we determined whether it
could promote a similar effect in these cells. 2-d treatments
with 1,25(OH)2D3 induced a nearly complete colocaliza-
tion of both proteins at the region of the plasma membrane
in contact with neighboring cells (Fig. 5, top). An identical
effect was observed when untreated SW480-ADH cells were
transfected with an E-cadherin expression plasmid (Fig. 5,
top). As controls, we used VDR-negative SW480-R cells,
which did not show any change in the strong nuclear -cate-
nin staining upon 1,25(OH)2D3 addition (Fig. 5, bottom).
As expected, exogenous E-cadherin caused the same change
in -catenin localization as in SW480-ADH cells (Fig. 5,
bottom). To correlate the change in -catenin localization
induced by 1,25(OH)2D3 with the effects on -catenin–
TCF/LEF-1 target genes as a function of time, we studied
the kinetics of -catenin nuclear export. To this end, we
analyzed the immunofluorescence of SW480-ADH cells
stained with an anti–-catenin antibody by confocal laser
microscopy and counted the cells displaying predominantly
nuclear, a mixed nuclear-cytosolic, or an exclusively mem-
Table I. Induction by 1,25(OH)2D3 of TER in SW480-ADH cells
TER
Time Control 1,25(OH)2D3
d cm2
0 8.3 20.7
1 8.3 33.2
2 12.4 41.5
3 12.4 58.1
4 12.4 70.5
5 12.4 66.4
6 12.4 70.6
7 12.4 91.3
8 16.6 83.1
Cells pretreated during 30 d with either 1,25(OH)2D3 (107) or vehicle
were then cultured on Transwells, and resistance measurements were
performed as described in Materials and methods during the following 8 d
under the same treatments. Mean values of triplicate cultures are shown.
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branous -catenin localization (Fig. 6 A, insets). The num-
ber of nuclear-positive -catenin cells clearly decreased
(from 66 to 24%) as soon as 16 h after 1,25(OH)2D3 addi-
tion, was further reduced (to 10%) at 48 h, and was ex-
tremely low (around 2%) 7 d later (Fig. 6 A, white bars).
Conversely, the proportion of cells with predominant mem-
brane-bound -catenin increased progressively from 11% in
nontreated cultures to 70% after 7 d of 1,25(OH)2D3
treatment (Fig. 6 A, black bars).
Therefore, we aimed to examine the putative effects of
1,25(OH)2D3 on -catenin signaling. First, we checked
whether TCF-4 RNA expression was modified by 1,25
(OH)2D3 or not as in the case of -catenin. No changes
were detected by Northern and Western blotting (unpub-
lished data). To measure -catenin–mediated transcription,
we used a reporter gene placed under the control of a pro-
moter constructed by fusing three copies of the TCF/LEF-1
consensus responsive sequence and a c-fos minimal promoter
(TOP-flash). A mutated form of this plasmid (FOP-flash)
was used as negative control. 1,25(OH)2D3 effectively in-
hibited -catenin–TCF/LEF-1 transcriptional activity in
transfected SW480-ADH cells (Fig. 6 B). Moreover, since
these cells express a mutant APC protein and 1,25
(OH)2D3 did not modify -catenin levels this result shows
that wild-type APC is not required by 1,25(OH)2D3 to in-
hibit -catenin signaling.
Next, we analyzed the regulation of endogenous -cate-
nin–TCF/LEF-1 target genes. 1,25(OH)2D3 reduced the
cellular RNA levels of c-myc, Tcf-1, CD44, and PPAR
genes induced by -catenin–TCF/LEF-1 (He et al., 1998,
Figure 3. Induction of E-cadherin expression by 1,25(OH)2D3. (A) Northern blot analysis of E-cadherin and -catenin mRNA expression in 
SW480-ADH, SW480-R, and SW620 cells untreated or treated with 107 M 1,25(OH)2D3 for 48 h. 10 	g of poly(A)
 RNA was loaded per 
lane. GAPDH was used as an internal control. (B) Western blot analysis of E-cadherin and -catenin protein expression in the same condi-
tions. (C) Specificity of 1,25(OH)2D3 action. Northern blot analysis of E-cadherin mRNA expression in SW480-ADH cells untreated or 
treated with 107 M of the indicated agent or the corresponding vehicles for 48 h. Conditions were as above. (D) Northern blot analysis of the 
kinetics of induction of E-cadherin mRNA by 1,25(OH)2D3 in SW480-ADH cells. Times of treatment are indicated. Conditions were as 
above. (E) Western blot analysis of the kinetics of induction of E-cadherin protein by 1,25(OH)2D3 in SW480-ADH cells. Times of treatment 
are indicated. (F) Quantification of the induction by 1,25(OH)2D3 in SW480-ADH cells of E-cadherin mRNA () and protein () and of
-catenin mRNA () and protein (). Fold increase with respect to expression in untreated cells (time 0) is represented. Mean values of three 
experiments are shown. Quantifications were performed using NIH image software.
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1999; Roose et al., 1999; Vera et al., 1999) (Fig. 6, C and
D). They were downregulated with biphasic kinetics: a rapid
(4–8 h) and slight (25–30%) reduction followed (after 48 h)
by an additional diminution (to 50–80%) when -catenin
was no longer present into the nucleus. Though in untreated
cells c-myc and CD44 RNA levels increased during incubation
probably due to the proliferation status, 1,25(OH)2D3 al-
ways had an inhibitory effect. In addition, 1,25(OH)2D3
also rapidly induced the expression of ZO-1 (Fig. 6, C and D),
which is repressed by -catenin–TCF/LEF-1 (Mann et al.,
1999). Like -catenin, ZO-1 is involved in intercellular adhe-
sion and perhaps signaling (Gottardi et al., 1996). This in-
crease was confirmed at the protein level by immunofluores-
cence and confocal microscopy analyses (Fig. 6 E). In
untreated SW480-ADH cells, ZO-1 showed a diffuse cy-
toplasmic and punctate nuclear localization. 16 h after
1,25(OH)2D3 addition, the cellular content of ZO-1 clearly
increased and was also located in cell-to-cell contact areas. At
48-h after treatment, the subcellular distribution of ZO-1 was
drastically altered, since it was almost completely peripheral.
Thus, 1,25(OH)2D3 has a dual effect on ZO-1: it relieves the
repression by -catenin–TCF/LEF-1 at the transcriptional
level, and it induces the redistribution of ZO-1 protein to the
plasma membrane. This relocation was concomitant with that
of -catenin in accordance with the nuclear coexport of ZO-1
and catenins that takes place during the differentiation of
MDCK epithelial cells (Rajasekaran et al., 1996). Although
cyclin D1 has been proposed as a -catenin–regulated gene
(Tetsu and McCormick, 1999), neither cyclin D1 RNA nor
protein expression were modified upon 1,25(OH)2D3 addi-
tion to SW480-ADH cells (unpublished data). These data in-
dicate that in SW480-ADH cells 1,25(OH)2D3 downregu-
lates -catenin–TCF/LEF-1 target genes.
To examine how general the effects of 1,25(OH)2D3 ob-
served in SW480-ADH cells were, we extended the study to
other human colon carcinoma cell lines such as Caco-2,
SW1417, HT-29 M6, and LS-147T. As in SW480-ADH
cells, 1,25(OH)2D3 induced a parallel activation (two- to
fourfold) of a VDRE–reporter construct and an inhibition of
-catenin–TCF-4 transcriptional activity (25–50%) (Fig. 7 A).
SW480-R and SW620 cells were used as negative control. In
addition, E-cadherin expression was increased (two- to three-
fold after 48 h) by 1,25(OH)2D3 in these cell lines but in LS-
174T, which were totally defective for this protein (Fig. 7 B).
VDR and -catenin interact in a ligand-regulated manner
The rapid changes in the RNA levels of target genes after
1,25(OH)2D3 treatment, which occurred earlier than the
induction of -catenin nuclear export, suggested additional
mechanisms of action for 1,25(OH)2D3. We tested
whether VDR and -catenin interacted, thus affecting the
formation of -catenin–TCF-4 complexes. To this end, in
vitro–translated VDR was incubated with either glutathione
S-transferase (GST)–-catenin or GST proteins in the pres-
ence or absence of 1,25(OH)2D3. After precipitation with
GSH–Sepharose beads, the presence of VDR in the precipi-
tates was tested by immunoblotting using an anti-VDR anti-
body, revealing a direct mostly ligand-independent VDR–
-catenin interaction (Fig. 8 A). To determine whether
VDR and -catenin form complexes in vivo, extracts from
Figure 4. Mechanism of E-cadherin gene induction by 
1,25(OH)2D3. (A) Northern blot analysis of E-cadherin mRNA expres-
sion in SW480-ADH cells untreated or treated with 107 M 
1,25(OH)2D3 for 4 h. Where indicated, cells were pretreated with ac-
tinomycin D (Act D, 2 	g/ml) or cycloheximide (CHX, 8 	g/ml) 30 
min before 1,25(OH)2D3 addition. 10 	g of poly(A)
 RNA was 
loaded per lane. GAPDH was used as an internal control. (B) Activa-
tion of the human E-cadherin gene promoter by 1,25(OH)2D3. 
SW480-ADH cells were transfected with either 987-TK-Luc plasmid, 
which contains the genomic sequence from 
92 to 987 bp, or 
178-TK-Luc containing the sequence from 
92 to 178 bp of the 
human E-cadherin gene. The empty TK-Luc vector was used as con-
trol. Transfections were performed as described in Materials and meth-
ods. White bars, untreated cells; black bars, cells treated with 107 M 
1,25(OH)2D3 during 48 h after transfection. Mean values correspond-
ing to five independent experiments done in triplicate are shown. (C) 
Lack of effect of 1,25(OH)2D3 on E-cadherin mRNA stability. SW480-
ADH cells were pretreated or not pretreated for 30 min with actinomy-
cin D (2 	g/ml) and then incubated in the presence () or absence () 
of 1,25(OH)2D3 (107 M), during the indicated times. Northern blot 
analysis of E-cadherin and GAPDH mRNA expression. Conditions 
were as above. Two independent experiments gave the same result.
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Figure 5. Induction of colocalization of E-cadherin and -catenin at the plasma membrane by 1,25(OH)2D3. Analysis by immunofluores-
cence and confocal laser scanning microscopy of the expression of these two proteins in SW480-ADH or SW480-R cells at 48 h after either 
treatment with 1,25(OH)2D3 (107 M) or transfection with an expression vector for human E-cadherin. Double immunofluorescence was 
performed using anti–E-cadherin and anti–-catenin antibodies followed by the addition of the corresponding secondary TRICT-conjugated 
(E-cadherin, red) or FITC-conjugated (-catenin, green) antibodies. The merge of both signals (yellow) indicates the areas of colocalization of 
both proteins. Bars, 10 	m.
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Figure 6. Inhibition of the -catenin–TCF-4 signaling by 1,25(OH)2D3. (A) 1,25(OH)2D3 induces nuclear export of -catenin. Quantifica-
tion of the percentage of SW480-ADH cells showing predominant nuclear (left inset, white bars), mixed nuclear-cytoplasmic (middle inset, 
gray bars), or exclusively membranous (right inset, black bars) -catenin localization after treatment with 1,25(OH)2D3 (107 M) for the indi-
cated times. 500 cells were analyzed at each time point. (B) Inhibition of -catenin–TCF-4 transcriptional activity by 1,25(OH)2D3. SW480-
ADH cells were transfected with the wild-type (TOP-flash) or mutated (FOP-flash) -catenin–TCF4/LEF-1–sensitive reporter plasmids and then 
left untreated (white bars) or treated (black bars) with 1,25(OH)2D3 (107 M) for 48 h. Mean values and standard deviation of the mean of 
triplicated obtained in three experiments are shown. (C) Effects of 1,25(OH)2D3 on the expression of -catenin–TCF-4 target genes. Northern 
blots analysis of mRNA expression in SW480-ADH cells untreated or treated with 107 M 1,25(OH)2D3 for the indicated times. Conditions 
were as above. (D) Quantification of the change in ZO-1, PPAR, CD44, Tcf-1, and c-myc mRNA levels induced by 1,25(OH)2D3. Mean 
values and error bars corresponding to triplicates obtained in three experiments are shown. (E) Induction and redistribution of ZO-1 protein 
by 1,25(OH)2D3 treatment. Analysis by immunofluorescence and confocal laser microscopy of ZO-1 expression in SW480-ADH cells after 
addition of 1,25(OH)2D3 (107 M). Bar, 10 	m.
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cells incubated with 1,25(OH)2D3 for various periods were
immunoprecipitated with either anti–-catenin or anti-VDR
antibodies and then subjected to immunoblotting with the
opposite antibody. 1,25(OH)2D3 rapidly (4 h) enhanced
the VDR–-catenin interaction (Fig. 8 B). Conversely,
1,25(OH)2D3 decreased the amount of TCF-4 present in
-catenin immunoprecipitates (Fig. 8 B), suggesting that
VDR and TCF-4 compete for -catenin binding. 48 h after
treatment, the level of VDR–-catenin interaction was simi-
lar to that of untreated cells, probably because of the strong
induction of E-cadherin, which leads to -catenin sequestra-
tion at the cell junctions. In fact, coimmunoprecipitation us-
ing anti–E-cadherin and anti–-catenin antibodies revealed
the formation of E-cadherin–-catenin complexes, which re-
placed VDR–-catenin complexes as early as 16 h after
1,25(OH)2D3 treatment in the same extracts (Fig. 8, B–F).
We would like to point out that the change in complex for-
mation was concomitant with E-cadherin protein induction
and phenotypic modulation by 1,25(OH)2D3. Similar re-
sults were obtained when the presence of -catenin was de-
termined in VDR immunoprecipitates. Differences in the
amount of -catenin–VDR complexes immunoprecipitated
with one or the other antibodies at 16 h after 1,25(OH)2D3
addition must be attributed to differences in affinity and/or
epitope recognition. As stated above, 1,25(OH)2D3 did not
modify the cellular content of VDR, whereas in the case of
-catenin and TCF-4 the apparent changes were due to the
weak extracting conditions used to preserve protein–protein
interactions in these assays (Fig. 8 B). However, no changes
in total -catenin, VDR, or TCF-4 levels were detected un-
der strong solubilization conditions as mentioned above (un-
published data). As expected, no VDR–-catenin complexes
were detected in SW480-R cells expressing only residual
amounts of VDR (Fig. 8 G) that were unable to mediate
VDRE activation (Fig. 1 C and Fig. 7).
Functional interplay between VDR, -catenin, and TCF-4
Given that -catenin is a transcriptional coactivator and in-
teracts with VDR, we examined whether it enhances the ac-
tivation of a VDRE by 1,25(OH)2D3. To this end, we
used a plasmid encoding a stable form of -catenin resistant
to APC-induced degradation in which the GSK-3 target
Ser37 residue is mutated to Ala (S37A) (Easwaran et al.,
1999). Exogenous -catenin S37A expression did not mod-
ify VDRE activation in SW480-ADH or SW480-R cells,
probably because of the high level of endogenous nuclear
-catenin (Fig. 9 A). To circumvent this problem, we trans-
fected human MCF-7 mammary epithelial cells containing
extremely low amounts of nuclear -catenin. In these cells,
-catenin S37A fostered the induction by 1,25(OH)2D3 of
Figure 7. 1,25(OH)2D3 regulates VDR and -catenin–
TCF-4 transcriptional activity and E-cadherin expression 
in multiple human colon cancer cell lines. (A) Activation 
of VDR (top) and inhibition of -catenin–TCF-4 transcrip-
tional activity (bottom) by 1,25(OH)2D3. Cells were 
transfected with either the 4  VDRE–DR3-tk-luc con-
struct (top) or the TOP-flash plasmid (bottom) and then 
treated or not with 1,25(OH)2D3 (107 M) for 48 h in 
DME supplemented with 0.5% FCS. SW480-R and 
SW620 cells were used as negative control. Mean values 
and standard deviation of the mean of triplicated ob-
tained in two or three experiments after normalization are 
shown. (B) Effect of the same 1,25(OH)2D3 treatment on 
the expression of E-cadherin in the same cell lines. 20 	g 
of total cell protein extracts (with the exception of 60 	g 
in the case of LS-174T cells) were analyzed by Western 
blot. The result shown is representative of two or three ex-
periments performed with each cell line. Quantification 
of the stimulation by 1,25(OH)2D3 is shown below.
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a consensus VDRE from 6- to 49-fold (Fig. 9 B). In con-
trast, -catenin S37A did not affect the basal VDRE levels
in untreated cells (unpublished data). No such effect was ob-
served on thyroid or glucocorticoid hormone response ele-
ments or on a B-dependent construct (unpublished data).
In contrast to -catenin, exogenous TCF-4 caused a twofold
reduction in VDRE activation in SW480-ADH (over en-
dogenous VDR) and SW480-R (over exogenous VDR) cells
(Fig. 9 A), further supporting the hypothesis that VDR and
TCF-4 compete for -catenin binding. A dose-response as-
say of transfection of increasing amounts of TCF-4 expres-
sion plasmid in SW480-ADH cells confirmed that TCF-4
hinders VDR activity (Fig. 9 C). In contrast, a mutant TCF-4
lacking the NH2-terminal region required for -catenin
binding (-TCF-4) was unable to inhibit VDR activity
(Fig. 9 C). Additionally, the inhibition of VDRE activation
by TCF-4 was completely reversed by cotransfection of
-catenin S37A (Fig. 9 C).
Next, we examined whether ligand-activated VDR inhib-
its the transcriptional activity of -catenin–TCF/LEF-1
complexes regardless of E-cadherin induction. To this end,
we transfected -catenin and TCF-4 in Pam212, a kerati-
nocyte murine cell line expressing high amounts of E-cad-
herin and lacking nuclear -catenin. In these cells, which ex-
press only residual levels of VDR, the activation of the
TOP-flash reporter by -catenin–TCF-4 was inhibited
(greater than threefold) by 1,25(OH)2D3 upon ectopic ex-
pression of VDR (Fig. 8 D) without concomitant induction
of E-cadherin as assessed by Western blotting (unpublished
data). This result is in line with those obtained in LS-174T
cells in which 1,25(OH)2D3 induces VDRE activation and
inhibits -catenin–TCF-4 transcriptional activity in spite of
a total lack of E-cadherin induction (Fig. 7 B).
Nonhypercalcemic vitamin D3 analogues are potent 
inhibitors of the -catenin signaling pathway
Three synthetic vitamin D analogues with low calcemic
properties, EB1089, KH1060, and MC903, used currently
in clinical trials to treat several neoplasias (see Introduction
for references) were studied for their effects on -catenin sig-
naling in SW480-ADH cells. Like 1,25(OH)2D3, all three
analogues displayed antiproliferative activity (unpublished
data). We then studied whether these compounds induce
the expression of E-cadherin mRNA and protein by North-
Figure 8. Induction of VDR–-catenin 
interaction by 1,25(OH)2D3. (A) Inter-
action in vitro. In vitro–translated human 
VDR and bacterially produced GST–
-catenin were incubated in the pres-
ence or absence of 1,25(OH)2D3 as
described in Materials and methods. 
Western blot (WB) analysis using a spe-
cific anti-VDR antibody of the material 
precipitated upon incubation with GSH–
Sepharose beads. GST alone was used in 
parallel to rule out unspecific binding. 
(B) Interaction in vivo. Extracts of 
SW480-ADH cells untreated or treated 
with 1,25(OH)2D3 (107 M) for the indi-
cated times were subjected to immuno-
precipitation (IP) with anti-VDR, or
-catenin, or anti-E-cadherin antibodies 
followed by Western blot with the anti-
bodies indicated in each case. Western 
blot analysis showing the proportion of 
each protein present in the lysates. (C) 
Quantification of the amount of -cate-
nin bound to VDR after 1,25(OH)2D3 
addition. (D) Quantification of the 
amount of VDR bound to -catenin after 
1,25(OH)2D3 addition. (E) Quantifica-
tion of the amount of TCF-4 bound to
-catenin after 1,25(OH)2D3 addition. 
(F) Quantification of the amount of
-catenin bound to E-cadherin after 
1,25(OH)2D3 addition. (G) Absence of 
VDR–-catenin coimmunoprecipita-
tion in SW480-R cells. Extracts of 
SW480-R cells untreated or treated with 
1,25(OH)2D3 (107 M) for the indicated 
times were subjected to immunoprecipi-
tation with anti-VDR antibody followed 
by Western blotting using anti–-catenin 
antibody. Western blot analysis of the ly-
sates show the presence of only residual 
level of VDR.
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ern and Western blotting. As 1,25(OH)2D3, doses in the
1011–107 M range of each compound induced E-cadherin
expression (Fig. 10 A). All three compounds reduced the
expression of a -catenin–TCF-4 reporter construct in
SW480-ADH cells (Fig. 10 B). The effects observed in the
assays show that EB1089 and KH1060 are more potent
than 1,25(OH)2D3, whereas MC903 is less active. In
agreement with our previous results, all three analogues pro-
moted the morphological differentiation and nuclear export
of -catenin in SW480-ADH cells but had no effect in
VDR-defective SW480-R or SW620 cells as revealed by im-
munofluorescence (Fig. 10 C).
Discussion
Our results show that 1,25(OH)2D3 and several nonhyper-
calcemic analogues used currently in clinical trials as po-
tential anticancer drugs induce the differentiation of hu-
man colon carcinoma cells. They promote a phenotypic
change involving the induction of E-cadherin expression
and the blockade of the -catenin gene regulatory activity in
SW480-ADH cells.
1,25(OH)2D3 inhibits the transcriptional activity of
-catenin by two mechanisms. On the one hand, it rapidly
increases the amount of VDR bound to -catenin, block-
ing the interaction of this catenin to TCF-4. Therefore,
1,25(OH)2D3 modulates TCF/LEF-1 target genes in a
manner opposite to -catenin. In some cells, such as
Pam212 and LS-174T, this effect is independent of changes
in E-cadherin expression. Secondly, in SW480-ADH cells
changes in -catenin transcriptional activity caused by
1,25(OH)2D3 are accompanied by the nuclear export of
-catenin and its relocalization to the plasma membrane
that happens concomitantly to E-cadherin protein expres-
Figure 9. Modulation of the transcriptional 
activity of VDR by -catenin and TCF-4. (A) 
SW480-ADH and SW480-R cells were trans-
fected with the 4  VDRE–DR3-Tk-Luc con-
struct in combination with expression vectors 
for VDR, -catenin S37A, or TCF-4 as indi-
cated. Luciferase activity was measured in
extracts of cells untreated or treated with 
1,25(OH)2D3 (107 M) for 48 h. (B) -Catenin 
enhances VDRE activation in MCF-7 cells. 
Cells were cotransfected with 4  VDRE–DR3-
Tk-Luc and increasing amounts of -catenin 
S37A expression vector. (C) TCF-4 inhibits 
VDRE activation in SW480-ADH cells. Cells 
were cotransfected with 4  VDRE–DR3-Tk-
Luc construct and variable amounts of expres-
sion vectors for wild-type TCF-4, the mutant 
N-TCF-4, or -catenin S37A as indicated. 
Conditions and measurements were as above. In 
A–C, VDRE activation is represented as fold in-
crease in treated versus untreated cells. (D) 
1,25(OH)2D3 inhibits -catenin–TCF-4 tran-
scriptional activity in Pam212 cells. Cells were 
co-transfected with TOP-flash or FOP-flash re-
porter constructs and with expression vectors for 
-catenin, TCF-4, and VDR as indicated. 
1,25(OH)2D3 (107 M) was added 24 h after 
transfection, and cell extracts were prepared
24 h later. Fold increase values of luciferase ac-
tivity (TOP/FOP) after normalization were calcu-
lated. In A–D, mean values and standard devia-
tion of the mean obtained in duplicates of three 
independent experiments are shown.
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Figure 10. Nonhypercalcemic 1,25(OH)2D3 de-
rivatives induce E-cadherin and inhibit -catenin–
TCF-4 transcriptional activity in SW480-ADH 
cells, causing -catenin nuclear export and mor-
phological differentiation. (A) Northern and West-
ern blot analyses of E-cadherin expression in cells 
treated for 24 h and 48 h, respectively, with various 
doses of 1,25(OH)2D3, MC903, KH1060, or 
EB1089. Conditions were as above. (B) -catenin–
TCF-4 transcriptional activity in cells transfected 
with the TOP-flash and FOP-flash constructs and 
treated 48 h with 107 M of the indicated com-
pound. Mean values and standard deviation of the 
mean obtained in duplicates of two independent 
experiments are shown. (C) Induction of differentia-
tion and nuclear export of -catenin. Immunofluo-
rescence and confocal laser microscopy analysis of 
-catenin expression was done as before. SW480-R 
and SW620 cells were used as negative control.
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sion. 1,25(OH)2D3 might enhance the sequestration of
-catenin in the plasma membrane compartment by E-cad-
herin or alternatively might stimulate -catenin nuclear ex-
port, a process mediated by APC (Henderson, 2000; Rosin-
Arbesfeld et al., 2000). Alternatively, 1,25(OH)2D3 may
stimulate the APC-independent -catenin export described
recently (Eleftheriou et al., 2001). Although an estimation
of the respective contribution of these activities to the inhi-
bition of -catenin signaling is very difficult, their respective
timing supports the hypothesis that the primary effect is due
to the formation of VDR–-catenin complexes. By favoring
this, 1,25(OH)2D3 may indirectly regulate the transcrip-
tion of -catenin–TCF/LEF-1 target genes such as Tcf-1,
CD44, PPAR, and ZO-1. The changes in RNA content
for these genes after 1,25(OH)2D3 treatment occur earlier
than those in -catenin localization, which suggests that
they are initiated as a result of the VDR–TCF-4 competi-
tion for -catenin and later strengthened by the nuclear ex-
port of -catenin.
The physical interaction of VDR with -catenin adds to
that reported previously for retinoic acid receptor (RAR)
(Easwaran et al., 1999). However, the interaction of -cate-
nin with these two nuclear receptors differs. RAR strictly de-
pends on ligand binding, whereas a certain amount of VDR–
-catenin complexes were found in vitro in the absence of
1,25(OH)2D3. In contrast, this basal interaction augments
in the presence of 1,25(OH)2D3 in vivo, suggesting the
participation of ligand-dependent nuclear mediator(s) or
mechanism(s). However, given the high activity of 1,25
(OH)2D3 in our cell system, low amounts of metabolically
active vitamin D derivatives in the culture medium may be
sufficient to activate VDR in the absence of added agent.
Likewise, the stimulation by -catenin of the effect of 1,25
(OH)2D3 on a VDRE-dependent promoter agrees with that
reported for RAR-responsive promoters (Easwaran et al.,
1999). In vivo, the interaction between VDR and -catenin
may ameliorate -catenin–TCF-4 signaling. Upon -cate-
nin stabilization due to its mutation or that of APC, binding
to VDR may buffer its stimulatory action on TCF-4 target
genes, a protective effect which can be lost along with VDR
expression during malignant progression. Additionally, our
data suggest that nuclear -catenin might transiently poten-
tiate VDR transcriptional activity before -catenin moves
out of the nucleus and/or VDR is extinguished.
The -catenin homologue -catenin/plakoglobin is also
regulated by APC and functions as an oncogene (Kolligs et
al., 2000). Like -catenin, it activates c-myc expression in
APC-mutated cells, which together with mutations in its
NH2-region is thought to be critical for its oncogenic activ-
ity (Kolligs et al., 2000). -Catenin/plakoglobin indirectly
activates TCF/LEF-1–regulated genes by increasing the lev-
els of -catenin and by inducing its nuclear translocation
(Zhurinsky et al., 2000). These data show similarities but
also differences in the mechanism of action of -catenin and
-catenin/plakoglobin. 1,25(OH)2D3 induces the nuclear
export of -catenin/plakoglobin to the plasma membrane,
which may also contribute to the phenotypic change de-
scribed in this study.
Our results show the competition between VDR, TCF-4,
and E-cadherin for binding to -catenin. Since the E-cad-
herin gene has been proposed to be down-regulated by
-catenin upon binding of -catenin–TCF/LEF-1 to its
promoter (Huber et al., 1996) and 1,25(OH)2D3 induces a
concomitant increase in VDR–-catenin binding and E-cad-
herin mRNA, an effect on the E-cadherin promoter is plausi-
ble. The formation of VDR–-catenin complexes may re-
duce the -catenin binding to TCF-4 and so lead to a relief
of promoter repression and/or have a direct activating effect.
In disagreement with this hypothesis, VDR overexpression
in SW480-ADH cells did not increase the basal activation of
the 1.1-kb E-cadherin promoter construct, although poten-
tial regulatory sequences outside this region cannot be ruled
out. The moderate induction by 1,25(OH)2D3 of this
E-cadherin gene promoter construct does not unambigu-
ously demonstrate that E-cadherin gene is regulated tran-
scriptionally by this agent. However, this effect is consis-
tently observed, and together with the inhibitory action of
actinomycin and the lack of regulation of E-cadherin RNA
half-life suggests an effect at the transcription level.
Our data show that 1,25(OH)2D3 increases E-cadherin
gene transcription by a mechanism that is dependent on the
AF-2 domain of VDR and mediated by the novo synthesis of
short-lived proteins, although additional posttranscriptional
routes cannot be discarded. E-cadherin expression is inhib-
ited by the product of Snail gene, which is a transcriptional
repressor on the E-boxes located near the transcription start
site (Batlle et al., 2000; Cano et al., 2000). We show that
1,25(OH)2D3 regulates the human E-cadherin promoter
when a region of 1.1 kb upstream of the 
92 site is stud-
ied, but it has no effect on the activity of the proximal pro-
moter region that contains the E-boxes bound by Snail.
These data suggest that 1,25(OH)2D3 and Snail have oppo-
site effects on distinct sequences of the E-cadherin promoter.
Though no changes in Snail mRNA expression were detected
upon 1,25(OH)2D3 treatment, further research is required
to determine a putative interplay between these agents.
Whether the increase observed in the cellular content of
other intercellular adhesion proteins such as occludin, ZO-1,
ZO-2, and vinculin is a direct effect of 1,25(OH)2D3 or a
corollary of its primary effect on E-cadherin and/or -cate-
nin is unknown. Since the ZO-1 gene is repressed by -cate-
nin–TCF-4 (Mann et al., 1999) and ZO-1 mRNA increases
before E-cadherin protein levels are significantly elevated,
that is, when -catenin is abundant in the nucleus, the effect
of 1,25(OH)2D3 on this gene is probably due to the rapid
formation of VDR–-catenin complexes and the subsequent
reduction of -catenin–TCF-4 complexes. Additionally,
ZO-1 protein forms complexes with -, - and -catenins
(Rajasekaran et al., 1996), and like -catenin it can locate in
the cell nucleus where it may function as a signaling mole-
cule (Gottardi et al., 1996). In untreated SW480-ADH
cells, ZO-1 is distributed diffusely in the cytoplasm and in
intranuclear foci. Upon 1,25(OH)2D3 treatment, ZO-1 is
first increased and then redistributes to the cell surface as in
MDCK cells after E-cadherin expression (Rajasekaran et al.,
1996). The relevance of the effects of 1,25(OH)2D3 on
ZO-1 reported here is supported by a recent report describ-
ing the regulation of c-ErbB2/Neu expression by ZO-1
(Balda and Matter, 2000). It is also significant that other
genes regulated by 1,25(OH)2D3 in SW480-ADH cells
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play important roles: occludin expression has been associ-
ated with tumor differentiation (Kimura et al., 1997),
whereas vinculin is involved in the organization of tight
junctions (Watabe-Uchida et al., 1998). These changes are
consistent with the key role of E-cadherin in the mainte-
nance of epithelial characteristics and account for the drastic
change induced by 1,25(OH)2D3 in the differentiation sta-
tus of SW480-ADH cells.
The rapid inhibitory effect of 1,25(OH)2D3 on c-myc ex-
pression, another TCF/LEF-1–-catenin target gene, proba-
bly results from the combined effects of activities at various
levels, which take place before nuclear export of -catenin.
First, 1,25(OH)2D3 may induce the binding of regulatory
proteins to the first intron of the gene (Pan and Simpson,
1999). Second, the formation of VDR–-catenin complexes
may inhibit the activation by -catenin–TCF/LEF-1, as
may the alteration of -catenin/plakoglobin localization
(Kolligs et al., 2000).
The effects of 1,25(OH)2D3 in SW480-ADH cells are
transient and depend on its nuclear receptors. VDR content
is low in normal colon epithelial cells, increases at the early
stages of tumor progression, and is almost absent in the more
malignant carcinoma cells (Vandewalle et al., 1994). This
agrees with the finding that 1,25(OH)2D3 inhibits prolifera-
tion in human rectal mucosa (Thomas et al., 1992) and with
its activity in the weakly tumorigenic SW480-ADH cells and
its inefficacy in the highly tumorigenic SW480-R cells. Our
data are consistent with the proposed protective role of di-
etary vitamin D or sunlight exposure and with the predictive
use of VDR expression in colon cancer biopsies. Our results
suggest that liganded VDR may hinder the loss of differentia-
tion and the increase in proliferation at the early stages of car-
cinogenesis. 1,25(OH)2D3 has a pleiotropic biological ac-
tivity with complex cell-specific antitumor properties that
include induction of apoptosis, growth arrest, inhibition of
invasiveness, and stimulation of differentiation. The pattern
of expression of the coactivators (SRC-1, CBP, GRIP-1/
TIF-2, and others) and corepressors (NCoR, SMRT, Alien)
(Polly et al., 2000; for review see McDonald et al., 2001) that
interact with VDR and the activation of other signaling path-
ways such as that of TGF- (Yanagisawa et al., 1999) may be
responsible for the effects of 1,25(OH)2D3 in a particular
cell type. Our data reveal a complex network of interactions
between cell junction proteins with signaling abilities such
as -catenin, -catenin/plakoglobin, and ZO-1 and nuclear
hormone receptors such as VDR, which together with other
signaling mediators regulate gene expression and the pheno-
type of epithelial cells in a combinatorial fashion.
In summary, we report here on a novel activity of
1,25(OH)2D3 in human colon carcinoma cells, consist-
ing of the induction of E-cadherin and the inhibition of
-catenin signaling, which has an antitumor effect in vivo.
1,25(OH)2D3 exerts these protective effects in SW480-
ADH cells carrying a panel of mutations in critical genes
such as p53, ras, and APC and expressing negligible amounts
of E-cadherin but overexpressing c-myc and in other human
colon cell lines expressing functional VDR. These results
point to the key role of VDR expression in colon carcino-
genesis and support the use of nonhypercalcemic vitamin D
derivatives for the treatment of this neoplasia.
Materials and methods
Cell culture
SW480, SW620, Caco-2, HT-29 M6, SW1417, LS-147T, MCF-7, and
Pam212 cells were grown in DME supplemented with 10% FCS. SW480-
ADH and SW480-R lines were obtained from SW480 by limit dilution and
cultured in the same medium. All experiments using 1,25(OH)2D3,
MC903, KH1060, and EB1089 (a gift from Dr. Lise Binderup, Leo Pharma-
ceutical Products, Copenhagen, Denmark) were performed in DME sup-
plemented with charcoal-treated FCS to remove liposoluble hormones.
1,25(OH)2D3 and deltanoids were dissolved in isopropanol, and dexa-
methasone, all-trans-retinoic acid, and 9-cis-retinoic acid (all from Sigma-
Aldrich) were dissolved in ethanol.
Cloning of the human E-cadherin gene promoter
A 178/
92 human E-cadherin promoter fragment was amplified by PCR
using Pfu DNA polymerase (Stratagene) and 5-GACTACGCGTACTC-
CAGGCTAGAGGGTCAC-3 and 5-GATCGATATCCGGGTGCGGTC-
GGGTCGGGCCGGGCA-3 as sense and antisense oligonucleotides, re-
spectively. The 987/
92 E-cadherin promoter fragment was amplified
using the same antisense oligonucleotide and 5-AGTCGGTACCGA-
GAGTGCAGTGGCTCACGC-3 as sense oligonucleotide. Fragments were
digested with MluI/EcoRV or SacI/NcoI restriction enzymes and inserted in
pGL3 reporter vector (Promega). Cloned fragments were sequenced in order
to rule out differences with respect to the published sequence (sequence
data available from GenBank/EMBL/DDBJ under accession no. L34545).
Antibodies
The following antibodies were used: rabbit polyclonal anti-VDR (sc-1008;
Santa Cruz Biotechnology, Inc.), mouse monoclonal anti–-catenin
(C19220; Transduction Laboratories), rat monoclonal anti–mouse E-cad-
herin (ECCD-2; a gift from Dr. M. Takeichi, Kyoto University, Kyoto, Ja-
pan), rabbit polyclonal antioccludin (71-1500; Zymed Laboratories), rabbit
polyclonal anti-ZO1 (61-7300; Zymed Laboratories), rabbit polyclonal
anti–ZO-2 (71-1400; Zymed Laboratories), rabbit polyclonal antivinculin
IgG (sc-7649; Santa Cruz Biotechnology, Inc.), goat anti–TCF-4 (sc-8632;
Santa Cruz Biotechnology, Inc.), FITC-conjugated goat anti–mouse IgG
(115-095-003; Jackson ImmunoResearch Laboratories), TRICT-conjugated
anti–rat IgG (112-025-003; Jackson ImmunoResearch Laboratories),
TRICT-conjugated anti–rabbit IgG (Jackson ImmunoResearch Laborato-
ries), goat anti–rabbit IgG (H 
 L) HRP-conjugated (67437; ICN Biomedi-
cals), goat anti–mouse IgG (H 
 L) HRP-conjugated (67428; ICN Biomedi-
cals), goat anti–rat IgG (H 
 L) HRP-conjugated (31472; Pierce Chemical
Co.), and rabbit anti–goat IgG (612762; ICN Biomedicals).
Immunostaining
Cells were rinsed four times in PBS, fixed in cold methanol for 30 s at
20C and rinsed in PBS. The nonspecific sites were blocked by incuba-
tion with PBS containing 1% BSA for 1 h at room temperature. Cells were
then washed four times in PBS and incubated with the primary antibodies
diluted in PBS containing 1% BSA for 1 h at room temperature or overnight
at 4C. After four washes with PBS, cells were incubated with secondary
antibodies for 45 min at room temperature, washed, and mounted in
VectaShield (Vector Laboratories). Confocal microscopy was performed
with a Bio-Rad Laboratories MRC-1024 laser scanning microscope
equipped with an Axiovert 100 invert microscope (ZEISS) at excitation
wavelengths of 488 nm (for FITC) and 543 nm (for TRICT). Each channel
was recorded independently, and pseudocolor images were generated and
superimposed. Images were processed by the Adobe Photoshop® 5.0 soft-
ware (Adobe Systems, Inc.).
RNA preparation and Northern analysis
Purification of poly(A)
 RNA was carried out as reported elsewhere
(Vennström and Bishop, 1982). Northern blots were performed on nylon
membranes (Nytran; Schleicher & Schuell) following standard protocols
(Sambrook et al., 1989). All probes were labeled by the random priming
method (Feinberg and Vogelstein, 1983). Hybridizations were carried out
overnight at 65C in 7% SDS, 500 mM sodium phosphate buffer, pH 7.2,
and 1 mM EDTA as described by Church and Gilbert (1984). Filters were
washed twice for 30 min each in 1% SDS and 40 mM sodium phosphate
buffer, pH 7.2, at 65C. The sizes of respective mRNAs were calculated us-
ing RNA ladder markers (Bio-Rad Laboratories). Membranes were exposed
to Hyperfilm™ MP films (Amersham Pharmacia Biotech). The following
probes were used: for VDR and RXR, the complete human cDNA; for
E-cadherin, a fragment (nucleotides 2209–2649) of human cDNA; for
-catenin, the whole mouse cDNA; for c-myc, the third exon of the human
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cDNA (donated by Dr. J. León, Facultad de Medicina, University of Can-
tabria, Santander, Spain); for CD44, the full-length human cDNA; for Tcf-1,
the full-length Tcf-1 (van de Wetering et al., 1991) (both donated by Drs.
E. Sancho and H. Clevers, University Medical Center, Utrecht, Nether-
lands); for ZO-1, a 558-pb fragment of the human cDNA obtained by re-
verse transcriptase-PCR with the 5-CTTAACTATGCCCAGTGG-3 and 5-
CTTGTGGTGAGTAAGGAG-3 oligonucleotides as sense and antisense
primers, respectively; for PPAR, a 407-bp fragment of the human cDNA
obtained by reverse transcriptase-PCR with the 5-CTACGGTGTTCATG-
CATGTGAG-3 and 5-CACAATGTCTCGATGTCGTGG-3 oligonucle-
otides as sense and antisense primers, respectively; and for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), the complete human cDNA.
Immunoprecipitation and Western blotting
Immunoprecipitation of whole cell extracts with specific antibodies was
carried out as described elsewhere (Lozano and Cano, 1998). Whole cell
extracts were prepared by washing the monolayers twice in PBS, and the
cells were lysed by incubation in RIPA buffer (150 mM NaCl, 1.5 mM
MgCl2, 10 mM NaF, 10% glycerol, 4 mM EDTA, 1% Triton X-100, 0.1%
SDS, 1% deoxycholate, 50 mM Hepes, pH 7.4, plus phosphatase- and
protease-inhibitor mixture [PPIM: 25 mM -glycerophosphate, 1 mM
Na3VO4, 1 mM PMSF, 10 	g/ml leupeptin, 10 	g/ml aprotinin]) for 15 min
on ice followed by centrifugation at 13,000 rpm for 10 min at 4C. Immu-
noprecipitated proteins were analyzed in 7.5% or 12% SDS-PAGE gels.
Immunoblotting of cell lysates or immunoprecipitates was performed by
protein transfer to Immobilon-P membranes (Millipore Corp.) and incuba-
tion with the appropriate specific antibody. Blots were developed using
the ECL detection system (Amersham Pharmacia Biotech).
In vitro protein–protein interaction
100 ng each of bacterially produced GST–-catenin protein and human
VDR translated in vitro in rabbit reticulocyte lysates (TNT® T7 Quick Kit;
Promega) were mixed with 500 	l of immunoprecipitation buffer (IB: 50
mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM CaCl2, 5 mM MgCl2, 1% NP-
40, 1% Triton X-100) and incubated for 1 h at 4C. GST–-catenin com-
plexes were collected by addition of glutathione–Sepharose 4B (Amer-
sham Pharmacia Biotech), washed twice with IB, and resuspended in
Laemmli sample buffer. Proteins in the complexes were analyzed in 7.5%
SDS-PAGE gels, which was followed by immunoblotting with the indi-
cated antibodies.
Transactivation assays
Nearly confluent cells were transfected in triplicate P-60 dishes using Lipo-
fectAMINE™ reagent (Life Technologies) following the manufacturer
guidelines. The 4  VDRE–DR3-Tk-Luc construct containing four copies
in tandem of a consensus DR3 response element for vitamin D cloned up-
stream of the herpes virus simplex thymidine kinase gene promoter and the
luciferase reporter gene was provided by Dr. C. Carlberg (Heinrich-Heine-
Universität, Düsseldorf, Germany). To study -catenin–TCF/LEF-1 tran-
scriptional activity, we transfected either TOP-flash and FOP-flash contain-
ing multimerized wild-type (CCTTTGATC) or mutated (CCTTTGGCC) TCF/
LEF-1–binding sites upstream of a minimal c-fos promoter driving lu-
ciferase gene expression (Korinek et al., 1997) (a gift from Dr. H. Clevers).
1 	g of human VDR cDNA (cloned in pSG5) or human wild-type TCF-4
(cloned in pcDNA3.1) or mutant TCF-4 (N-TCF-4 lacking the NH2-termi-
nal -catenin–interacting region in pcDNA3) (Baulida et al., 1999) and
-catenin S37A (cloned in pCGN; a gift from Dr. A. Ben-Ze`ev, The Weiz-
man Institute, Rehovot, Israel) were used for exogenous expression to-
gether with 0.25 	g of the reporter luciferase plasmids. For exogenous
E-cadherin expression, we used the complete murine cDNA (cloned in the
pBATEM2 vector; a gift from Dr. M. Takeichi, Kyoto University). The ex-
pression vectors for the truncated VDR lacking the 11 COOH-terminal
amino acids (AF2) (Jiménez-Lara and Aranda, 1999) and for other point-
mutated VDR (L417S and E420Q) (cloned in pSG5) were donated by Dr.
Ana Aranda (Instituto de Investigaciones Biomédicas). As internal control
of the transfection efficiency, 0.5 	g of the pRSV-LacZ containing a
-galactosidase reporter gene was used. Luciferase and -galactosidase
activities were measured 48 h after transfection.
Transepithelial electrical resistance
The functional integrity of tight junctions was assayed by measuring the electri-
cal resistance towards ion flux of epithelial cell layers cultured on porous tissue
culture inserts (3090; Falcon). We used the Millicell electrical resistance sys-
tem (Millipore Corp.) connected to the electrode system Endohm-24 (World
Precision Instruments) following the manufacturer guidelines. TERs were cal-
culated after subtracting the background given by a blank culture insert.
Proliferation assays
50,000 cells were seeded in 24-well dishes (Falcon) and incubated in nor-
mal growth medium in the presence or absence of the indicated concentra-
tions of 1,25(OH)2D3. 48-h later, cells were pulsed with 1 	Ci/ml 3H-thy-
midine for 3 h. At the end of the labeling period, the medium was removed
and the cells were rinsed twice with PBS and fixed with chilled 10%
trichloroacetic acid for 10 min. Trichloroacetic acid was then removed and
the monolayers were air-dried at room temperature for 20 min. Thereafter,
precipitated cellular macromolecules were dissolved in 500 	l of 0.1 N
NaOH-0.1% SDS, and 450 	l of each sample was diluted in 5 ml of scintil-
lation solution OptiPhase HighSafe (Wallac Scintillation Products). Radio-
activity was measured using a 1209 RackBeta counter (LKB Wallac).
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